Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism

References

• National Health Service (NHS) England. Venous thromboembolism. England: NHS; 2016. https://www.england.nhs.uk/patientsafety/venous-thromb/. Accessed May 2016
   Google Scholar
• LaMori JC, Shoheiber O, Mody SH, et al. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States. Clin Ther 2015;37:62-70
   PubMed Web of Science ®Google Scholar
• House of Commons Health Committee Report on the Prevention of Venous Thromboembolism in Hospitalised Patients. England: House of Commons Health Committee; 2016. http://www.parliament.the-stationery-office.co.uk/pa/cm200405/cmselect/cmhealth. Accessed May 2016
   Google Scholar
• Ruppert A, Lees M, Steinle T. Clinical burden of venous thromboembolism. Curr Med Res Opin 2010;26:2465-73
   PubMed Web of Science ®Google Scholar
• Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005;11:663-73
   PubMedGoogle Scholar
• Casciano JP, Dotiwala Z, Kemp R, et al. Economic burden of recurrent venous thromboembolism: analysis from a U.S. hospital perspective. Am J Health Syst Pharm 2015;72:291-300
   PubMed Web of Science ®Google Scholar
• Donze J, Lipsitz S, Bates DW, et al. Causes and patterns of readmissions in patients with common comorbidities: retrospective cohort study. BMJ 2013;347:f7171
   PubMed Web of Science ®Google Scholar
• Department of Health. Payment by results guidance for 2012–13. Gateway reference 17250. London: Department of Health; 2012.
   Google Scholar
• Kristensen SR, Bech M, Quentin W. A roadmap for comparing readmission policies with application to Denmark, England, Germany and the United States. Health Policy 2015;119:264-73
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. Technology appraisal guidance [TA341] England: NICE; 2015. http://www.nice.org.uk/guidance/indevelopment/gid-tag474. Accessed May 2016
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. NICE technology appraisal guidance [TA287] England: NICE; 2013. https://www.nice.org.uk/guidance/ta287. Accessed May 2016
   Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708
   PubMed Web of Science ®Google Scholar
• Lanitis T, Leipold R, Hamilton M, et al. Cost-effectiveness of apixaban versus other oral anticoagulants for the initial treatment of venous thromboembolism and prevention of recurrence. Clin Therap 2016;38:478-93
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Edoxaban tosylate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism, Evidence Review Group Report, TA354; England: NICE; 2015 Accessed May 2016
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. Technology appraisal guidance [TA327] England: NICE; 2014. http://www.nice.org.uk/guidance/ta327/resources. Accessed May 2016
   Google Scholar
• Liu X, Johnson M, Mardekian J, et al. Apixaban reduces hospitalizations in patients with VTE: an analysis of the AMPLIFY trial. J Am Coll Cardiol 2014;63
   Web of Science ®Google Scholar
• Liu X, Thompson J, Phatak H, et al. Apixaban reduced hospitalizations in patients with venous thromboembolism: An analyisis of the AMPLIFY-EXT trial. Blood 2013;122:3638
   Web of Science ®Google Scholar
• Liu X, Johnson M, Mardekian J, et al. Apixaban reduces hospitalizations in patients with venous thromboembolism: An analysis of the apixaban for the initial management of pulmonary embolism and deep-vein thrombosis as first-line therapy (AMPLIFY) trial. J Am Heart Assoc 2015;4:1-8
   Web of Science ®Google Scholar
• Lee T, Masseria C, Breazna A, et al. Hospitalizations, recurrent venous thromboembolism or venous thromboembolism-related death, and major bleeding, by index event from the AMPLIFY trial. Vasc Med 2016;67:2256
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent venous thromboembolism events. Costing Template: Implementing NICE guidance. NICE technology appraisal guidance TA261; England: NICE; 2012
   Google Scholar
• Office for National Statistics. National Population Projections: 2014-based Statistical Bulletin England: Office for National Statistics; 2015. http://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/bulletins/nationalpopulationprojections/2015-10-29. Accessed May 2016
   Google Scholar
• Martinez C, Cohen AT, Bamber L, et al. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost 2014;112:255-63
   PubMed Web of Science ®Google Scholar
• Wilcox RR. Winsorized robust measures. Wiley StatsRef: Statistics Reference Online; 2014. http://onlinelibrary.wiley.com/doi/10.1002/9781118445112.stat06339/full. Accessed May 2016
   Google Scholar
• National Schedule of Reference Costs Year: 2014–15 - All NHS trusts and NHS foundation trusts - HRG Data. England: National Schedule of Reference Costs; 2014-2015. https://www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015
   Google Scholar
• Curtis L. Unit costs of health and social care 2012. Canterbury: Personal Social Services Research Unit, The University of Kent; 2012.
   Google Scholar
• Lee T, Masseria C, Breazna A, et al. Hospitalizations, recurrent venous thromboembolism or venous thromboembolism-related death, and major bleeding, by index event from the AMPLIFY trial. J Am Coll Cardiol 2016;67:2256
   Web of Science ®Google Scholar
• Fernandez MM, Hogue S, Preblick R, et al. Review of the cost of venous thromboembolism. ClinicoEconom Outcomes Res CEOR 2015;7:451-62
   PubMed Web of Science ®Google Scholar
• Sampson FC, Goodacre S, Kelly A-M, et al. How is deep vein thrombosis diagnosed and managed in UK and Australian emergency departments? Emerg Med J 2005;22:780-2
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Rivaroxaban in the treatment of deep vein thrombosis and prevention of recurrent venous thromboembolic events, Single Technology appraisal, TA261; England: NICE; 2011
   Google Scholar
• Zondag W, Kooiman J, Klok FA, et al. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J 2013;42:134-44
   PubMed Web of Science ®Google Scholar
• Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011;378:41-8
   PubMed Web of Science ®Google Scholar
• van Bellen B, Bamber L, Correa de Carvalho F, et al. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014;30:829-37
   PubMed Web of Science ®Google Scholar